What's new? Log in Free sign up

Bright Minds Biosciences (DRUG)

Company Profile

Company profile

Ticker

DRUG

Exchange

Website

brightmindsbio.com

CEO

Mr. Ryan E. S. K. Cheung B.Com., CA, CPA

Incorporated

British Columbia, Canada

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

BAYVIEW ACQUISITION CORP

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

DRUG stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

$34.60 mm in equity, sold $34.60 mm, 13 investors

Bright Minds Biosciences Closes US$35 Million Non-brokered Private Placement

$12.19 k in options / securities to be acquired, 1 investor

Current report (foreign)

Bright Minds Biosciences Announces US$35 Million Non-brokered Private Placement

Current report (foreign)

Current report (foreign)

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Current report (foreign)

Latest ownership filings

View all

RA CAPITAL MANAGEMENT, L.P.

Cormorant Asset Management, LP

COMMODORE CAPITAL LP

Logos Global Management LP

Point72 Asset Management, L.P.

Cormorant Asset Management, LP

PFM Health Sciences, LP

Financial summary

Financial statements Chart DRUG financial data

Quarter (USD)	Sep 23	Sep 22	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 23	Sep 22	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

DRUG institutional ownership history Ownership history

0.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3	0	NEW
Opened positions	3	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	12.92 mm	0.00	NEW
Total shares	11.55 k	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Jane Street	10.94 k	$11.81 mm	NEW
RY Royal Bank of Canada	510.00	$1.00 mm	NEW
Aspire Private Capital	100.00	$108.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Jane Street	10.94 k	+10.94 k	NEW
RY Royal Bank of Canada	510.00	+510.00	NEW
Aspire Private Capital	100.00	+100.00	NEW
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DRUG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Nov 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	21.7	184,331	4.00 mm	1,059,331
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	25.222	3,107	78.36 k	875,000
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	24.03	7,150	171.81 k	871,893
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	23.215	39,743	922.63 k	864,743
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	12.3513	4,609	56.93 k	825,000
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	11.7169	19,169	224.60 k	820,391
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	9.2624	2,700	25.01 k	801,222
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	8.804	2,600	22.89 k	798,522
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	7.3052	8,900	65.02 k	795,922
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	6.4247	33,343	214.22 k	787,022

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Baird Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $75

Baird analyst Joel Beatty initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $75.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

What's Going On With Bright Minds Biosciences Stock?

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly Neuroscience.

Bright Minds Biosciences On Friday Announced US$35M Non-Brokered Private Placement @USD$21.70/Share

Nasdaq Surges Over 100 Points; Schlumberger Reports Mixed Q3 Result

Press releases

From Benzinga Pro

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that further to its news release of October 18, 2024,

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ:DRUG), a biotechnology company focused on developing novel therapies for

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Peraso Inc. (NASDAQ:PRSO) specializes in advanced millimeter wave (mmWave) technology, a critical component of modern wireless communication systems. Their cutting-edge steerable beam technology, powered by a phased

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.